
    
      This clinical study is scheduled to be performed for the purpose of evaluating the safety and
      effectiveness of golimumab (CNTO148) administered in combination with stable dose
      (6-8mg/week) of methotrexate (MTX) to patients with rheumatoid arthritis (RA). CNTO148 50 mg
      group: CNTO148 50 mg SC injections every 4 weeks from the first administration until week
      152. If early escape, 100 mg SC injections every 4 weeks from week 16 until week 152. CNTO148
      100 mg group: CNTO148 100 mg SC injections every 4 weeks from the first administration until
      week 152 whether early escape or not Placebo group: Placebo SC injections every 4 weeks from
      the first administration until week 20 and then CNTO148 50mg SC injections every 4 weeks from
      week 16 until week 152
    
  